Scarica l'app Stockscreener
119.78
0.51%
-0.62
Dopo l'orario di chiusura:
120.14
0.36
+0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$120.40
Aprire:
$122
Volume 24 ore:
7.58M
Relative Volume:
1.05
Capitalizzazione di mercato:
$148.61B
Reddito:
$29.05B
Utile/perdita netta:
$8.11B
Rapporto P/E:
18.55
EPS:
6.4563
Flusso di cassa netto:
$9.16B
1 W Prestazione:
-1.16%
1M Prestazione:
-4.19%
6M Prestazione:
+8.91%
1 anno Prestazione:
+30.40%
Intervallo 1D:
$119.39
$122.98
Intervallo di 1 settimana:
$118.78
$123.74
Portata 52W:
$88.57
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
119.78 | 149.38B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,062.19 | 919.64B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
214.17 | 509.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.45 | 394.69B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.19 | 254.37B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.26 | 248.95B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead's experimental HIV treatment non-inferior to blockbuster drug in trial - Reuters
Gilead’s experimental HIV treatment meets main goal in late-stage trial - WTVB
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial - European AIDS Treatment Group
Gilead to start demolishing buildings for campus expansion by end of month - The Business Journals
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains - Investing.com
Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal - Benzinga
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meet - pharmiweb.com
Wolfe Research Adjusts Gilead Sciences PT to $150 From $140, Maintains Outperform Rating - marketscreener.com
Gilead Sciences Reports Positive Phase 3 ARTISTRY-2 HIV Trial Results - Nasdaq
Gilead (GILD) Hits Key Milestone with ARTISTRY-2 HIV Treatment T - GuruFocus
Gilead Yeztugo HIV combo pill meets goal in second phase 3 trial - Seeking Alpha
Gilead reports positive results for HIV treatment combination By Investing.com - Investing.com South Africa
Gilead Sciences, Inc. $GILD Shares Bought by Westwood Holdings Group Inc. - MarketBeat
Gilead (Nasdaq: GILD) to base HIV filings on Phase 3 ARTISTRY BIC/LEN trials - Stock Titan
Gilead Sciences, Inc. $GILD Shares Sold by Texas Permanent School Fund Corp - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Orion Porfolio Solutions LLC - MarketBeat
Gilead Sciences stock price target raised to $150 from $140 at Wolfe Research - Investing.com
Pitcairn Co. Grows Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Kestra Investment Management LLC Acquires 9,551 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
National Bank of Canada FI Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Farmers Trust Co. Sells 11,071 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
MASTERINVEST Kapitalanlage GmbH Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Thrivent Financial for Lutherans Sells 238,111 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Stance Capital LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Trimmed by China Universal Asset Management Co. Ltd. - MarketBeat
Continental Advisors LLC Sells 9,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Stock Traders Buy Large Volume of Gilead Sciences Call Options (NASDAQ:GILD) - MarketBeat
Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)? - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $151.00 at Morgan Stanley - MarketBeat
Treasurer of the State of North Carolina Has $85.51 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Acquires 140,158 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Benjamin Edwards Inc. - MarketBeat
BlueCrest Capital Management Ltd Buys Shares of 13,553 Gilead Sciences, Inc. $GILD - MarketBeat
AQR Capital Management LLC Has $272.21 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Ameriprise Financial Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead, Arcus scrap late-stage trial of cancer drug combo - 1470 & 100.3 WMBD
Gilead Sciences, Inc. $GILD Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure - BioSpace
GILEAD SCIENCES (GILD): Morgan Stanley Raises Price Target, Main - GuruFocus
Arcus cancels work on Gilead-partnered cancer combo after trial setback - BioPharma Dive
Arcus scraps late-stage cancer trial after weak survival data - Reuters
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com
Morgan Stanley Adjusts PT on Gilead Sciences to $151 From $147, Maintains Overweight Rating - marketscreener.com
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha
Gilead Sciences, Inc. $GILD Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
HUB Investment Partners LLC Has $5.49 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Sei Investments Co. Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
NewEdge Advisors LLC Has $11.81 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Alliancebernstein L.P. Sells 809,531 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer - Oncodaily
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.24%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):